Figure 4.

CuO-NPs inhibit pancreatic tumor growth in vivo. (A) Non-tumor bearing BALB/c mice were treated with CuO-NPs at doses ranging from 0–12.5 mg/kg Cu (n = 5 mice/group). Body weight was assessed over time. (B) Non-tumor bearing BALB/c mice were treated with CuO-NP at a dose of 1 mg/kg Cu (n = 4 mice/group). After 7 days, mice were bled by cardiac puncture, and serum was evaluated for biomarkers of hepatotoxicity. (C) PANC1 cells were subcutaneously implanted into the flanks of 6 week old NOD-SCID mice (n = 5 mice/group). When tumors reached 200 mm³, mice were injected with vehicle control or CuO-NPs (1 mg/kg Cu) daily for 7 sequential days. Tumor growth was monitored over time. (D) PANC1 cells tagged with luciferase, were orthotopically implanted in 6 week old NOD-SICD mice (n = 5 mice/group). On week 2, mice were injected with vehicle control or CuO-NPs (1 mg/kg Cu) daily for 7 sequential days. Tumor bioluminescence was assessed by IVIS on week 5, and bioluminescence measurements were plotted. Of note, mouse 5 in the treatment group is an outlier and removed from the quantification. *p < 0.05; **p < 0.01 as assessed by two-tailed student t test.